Jeffrey S. Berger, MD

About Me

Conditions and Treatments

heart attack, coronary heart disease, thrombosis, peripheral vascular disease (PVD), vascular disease occlusive, deep vein thrombosis (DVT), lung embolism, platelet disorders, antiplatelet therapy, high blood pressure disorder, lipid disorders, high cholesterol level, lipid metabolism, prediabetes, obesity
Show More Conditions
Learn more about conditions we treat at NYU Langone:
Lower Extremity Arterial Disease, Pulmonary Embolism, Obesity, Hypertension in Children

Credentials

Positions

  • Associate Professor, Department of Medicine
  • Associate Professor, Department of Surgery

Board Certifications

    2008
  • American Board of Internal Medicine (Cardiovascular Disease)

Education and Training

  • 2009
  • Fellowship, University of Pennsylvania, Vascular
  • 2008
  • Fellowship, Duke University Hospital, Cardiology
  • 2005
  • Residency, Beth Israel Medical Center, Medicine
  • 2001
  • MD from Tel Aviv University

Departments

Locations and Appointments

58 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Cigna EPO/POS
  • Cigna PPO
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Healthy NY
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • GHI CBP
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP EPO/PPO
  • HIP Family Health
  • HIP HMO
  • HIP Medicaid
  • HIP Medicare
  • HIP POS
  • HealthPlus Child Health (Amerigroup)
  • HealthPlus Family Health (Amerigroup)
  • HealthPlus Medicaid (Amerigroup)
  • HealthRepublic
  • HealthSmart (WTC)
  • Humana Medicare
  • MagnaCare PPO
  • Medicare
  • MetroPlus Child Health
  • MetroPlus Exchange Plans
  • MetroPlus Family Health
  • MetroPlus Medicaid
  • MultiPlan/PHCS PPO
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Exchange
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • Tricare
  • United Exchange- Compass
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • WellCare Child Health
  • WellCare Family Health
  • WellCare Medicaid
  • WellCare Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.

NYULMC Center for the Prevention of Cardiovascular Disease
530 1st Avenue, HCC, Suite 4F
New York, NY 10016

Contact

Phone: 212-263-7435

Schedule Online

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Dr Berger's research primarily focuses on discovering novel mechanisms of heart disease, peripheral vascular disease, and stroke. He is also interested in the etiology of unexplained thromboembolic (clotting) disease; 2) the clinical and cellular response to antithrombotic agents in cardiovascular disease; and 3) sex differences in the pathophysiology and treatment response of cardiovascular disease.

Dr. Berger has a particular interest in the field of platelet and hypercoagulable mechanisms of cardiovascular disease, with research interests that include: (1) the role of platelet activity in patients with different high risk vascular phenotypes, such as cardiac and peripheral atherosclerosis, aneurysmal disease, venous disease, kidney disease, and HIV; (2) regulation of platelet activity during the perioperative period; (3) the clinical and platelet response to antiplatelet and antithrombotic therapeutics; and (4) the study of personalized medicine using the platelet phenotype to guide therapeutics. Dr. Berger has set up a platelet lab to measure platelet activity using various techniques, including whole blood and platelet rich plasma aggregometry, flow cytometry, hematology analysis, and molecular biology using the platelet transcriptome. The overall goal of the lab is to use the platelet phenotype in understanding who is at risk for developing cardiovascular disease and to determine whether modification of the platelet phenotype can ultimately lower the risk of adverse cardiovascular events.

Publications

  • Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention

    Balakrishnan, Revathi; Berger, Jeffrey S; Tully, Lisa; Vani, Anish; Shah, Binita; Burdowski, Joseph; Fisher, Edward; Schwartzbard, Arthur; Sedlis, Steven; Weintraub, Howard; Underberg, James A; Danoff, Ann; Slater, James A; Gianos, Eugenia 2015 Feb; 611-612, Diabetes/metabolism research & reviews — id: 1480312, year: 2015, page: 611, stat: JOURNAL ARTICLE
  • Particulate Air Pollution and Carotid Artery Stenosis

    Newman, Jonathan D; Thurston, George D; Cromar, Kevin; Guo, Yu; Rockman, Caron B; Fisher, Edward A; Berger, Jeffrey S 2015 Feb; 1-5, Journal of the American College of Cardiology — id: 1494462, year: 2015, page: 1, stat: LETTER
  • The role of testosterone therapy in cardiovascular mortality: culprit or innocent bystander?

    Tanna, Monique S; Schwartzbard, Arthur; Berger, Jeffery S; Alukal, Joseph; Weintraub, Howard 2015 Mar; 490-490, Current atherosclerosis reports — id: 1466712, year: 2015, page: 490, stat: Journal Article
Read All Publications (117)